“…Despite this ability to yield useful data on the molecular pathology of neurodegeneration, use of these techniques is complicated by the extreme complexity of CNS tissues, which restricts the characterization of low-abundance proteins (Choudhary & Grant, 2004). Another drawback is the relative expense of the stable isotope labeling reagents and instrumentation required, which necessitates the pooling of samples from multiple individual subjects (Datta, Chen, & Sze, 2014;Datta et al, 2011Datta et al, , 2010Datta, Qian, et al, 2014;Dutta, Yan, Lim, Tam, & Sze, 2014). Yet another challenge associated with the use of quantitative proteomics to analyze brain tissues is the inability to assign the identified and characterized proteins to specific cell types in the affected tissues.…”